WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)

WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)

Saved in:

Bibliographic Details
Main Authors:	Jonathon Barratt, Anant Desai, Alessia Fornoni, Lesley Inker, Irene de Lourdes Noronha, Alejandra Quevedo, Robert Shepherd, Alisha Smith, Hernan Trimarchi, Lucila Valente, Mona Wahba, Muh Geot Wong, Hiddo Lambers Heerspink
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924012476
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
by: Howard Trachtman, et al.
Published: (2024-04-01)

Focal segmental glomerulosclerosis (FSGS) in pregnancy: The case of a 27-year-old woman with nephrotic syndrome at 22 weeks of gestation
by: Lucy Wang, et al.
Published: (2024-11-01)

A polymeric dexamethasone prodrug attenuates focal segmental glomerulosclerosis (FSGS) in an Adriamycin-induced mouse model with minimal glucocorticoid side effects
by: Haochen Jiang, et al.
Published: (2025-03-01)

Focal Segmental Glomerulosclerosis and Scheduled Pretransplant Plasmapheresis: A Timely Diagnosis of Nail-Patella Syndrome Avoided More Futile Immunosuppression
by: H. Trimarchi
Published: (2020-01-01)

A novel TRPC6 mutation that causes childhood FSGS.
by: Saskia F Heeringa, et al.
Published: (2009-11-01)

How to measure and monitor albuminuria in healthy toddlers?
by: Sophie Marielle van den Belt, et al.
Published: (2018-01-01)

WCN25-3862 Exploring the efficacy of Rituximab in treatment-resistant primary FSGS
by: Abhilash Chandra, et al.
Published: (2025-02-01)

WCN24-2091 A Case of Smoldering Atypical HUS Superimposed on Familial FSGS
by: Elias Bassil, et al.
Published: (2024-04-01)

WCN25-4459 Baseline parameters of patients with FSGS and MN enrolled in the ITANGIBLE registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

Bioinformatic identification of COLEC12 as a diagnostic biomarker and risk factor in pediatric FSGS
by: Lei Gao, et al.
Published: (2025-04-01)

WCN25-4287 TRANSPLANT OUTCOMES IN PATIENTS WITH PRIMARY FSGS: A SINGLE CENTRE EXPERIENCE
by: TIMITROV P, et al.
Published: (2025-02-01)

Familial focal segmental glomerulosclerosis in infancy
by: A Bakkaloğlu, et al.
Published: (1988-01-01)

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
by: Hiddo J.L. Heerspink, et al.
Published: (2025-04-01)

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

WCN24-1921 NEPHROTIC SYNDROME SECONDARY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS DUE TO PODOCYTE KANK-2 MUTATION
by: Sandra Liliana Borda Galindo, et al.
Published: (2024-04-01)

Functional analysis of heterozygous variants in the SALL1 gene in 2 children with Townes-Brocks syndrome with FSGS
by: Rong Liang, et al.
Published: (2025-02-01)

Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review
by: Jing Miao, et al.
Published: (2023-12-01)

Mucin-1 Gene Mutation and the Kidney: The Link between Autosomal Dominant Tubulointerstitial Kidney Disease and Focal and Segmental Glomerulosclerosis
by: H. Trimarchi, et al.
Published: (2018-01-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

Focal segmental glomerulosclerosis: current status of the problem
by: I. T. Murkamilov, et al.
Published: (2020-01-01)

The Novel Diagnostic Biomarkers for Focal Segmental Glomerulosclerosis
by: Mohsen Nafar, et al.
Published: (2014-01-01)

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
by: K. Melissa Hallow, et al.
Published: (2024-11-01)

WCN25-4408 Clinical Outcomes of FSGS with Nephrotic Syndrome at 1-Year: Findings from the ITANGIBLE Registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein.
by: June Yao, et al.
Published: (2004-06-01)

WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY
by: Richard Lafayette, et al.
Published: (2025-02-01)

WCN25-1081 STUDY OF CLINICAL SIGNIFICANCE OF IgM AND C3 GLOMERULAR DEPOSITIS IN PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
by: Prajit mazumdar, et al.
Published: (2025-02-01)

The compensatory enrichment of sphingosine-1-phosphate on HDL in FSGS enhances the protective function of glomerular endothelial cells compared to MCD
by: Yunfeng Xiong, et al.
Published: (2025-01-01)

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
by: Jiwon M. Lee, et al.
Published: (2019-01-01)

WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

Is the Prevalence of Focal and Segmental Glomerulosclerosis Increasing in the Province of Khuzestan?
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2012-05-01)

Nodular glomerulosclerosis with crescents- a double edged sword
by: Moumita Sengupta, et al.
Published: (2023-07-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts
by: Sean J. Barbour, et al.
Published: (2025-04-01)

Erratum to “Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287]
by: Sean J. Barbour, et al.
Published: (2025-07-01)

Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis
by: Wee Leng Gan, et al.
Published: (2018-10-01)

Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis
by: Wee Leng Gan, et al.
Published: (2018-10-01)

Dexamethasone induces transgenerational inheritance of fetal-derived glomerulosclerosis phenotype in offspring through GR/DNMT3a mediated alterations of the lncRNA-Meg3/Notch signaling pathway
by: Xiaoqi Zhao, et al.
Published: (2025-07-01)

WCN25-4200 RECURRENCE OF RECURRENT FSGS POST-TRANSPLANT IN A PEDIATRIC PATIENT: A THERAPEUTIC DILEMMA & CHALLENGES FACED
by: Asheesh Gupta, et al.
Published: (2025-02-01)

Combination of rituximab and low-dose glucocorticoids for idiopathic refractory nephrotic syndrome with MCD/FSGS: a single-center prospective cohort study
by: Aikeda Yimamuyushan, et al.
Published: (2024-12-01)

DOMÍNGUEZ SÁNCHEZ, Santiago (ed.) - Documentos pontificios medievales del monasterio de Santa María de Poblet (1132-1499). León: Universidad de León, Área de Publicaciones, 2017 (600 pp.)
by: Mariña Bermúdez Beloso
Published: (2020-01-01)